Results 111 to 120 of about 31,170 (214)
Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.ABSTRACT Rush Medical College implemented a new, integrated pre‐clerkship curriculum. Pharmacology was integrated with other basic sciences into a flipped, small‐group, case‐based structure. This report describes the main features of the pharmacology curriculum for pharmacology directors to have a template.
Brinda Desai Bradaric +3 more
wiley +1 more source
Optimal dose of losartan for renoprotection in diabetic nephropathy.
, 2002 BACKGROUND: Angiotensin II subtype-1 receptor antagonists represent a valuable new class of drugs in the treatment of diabetic nephropathy. The aim of our study was to evaluate the optimal dose of losartan for renoprotection and blood pressure reduction ...
Deinum, J. +9 more
core +1 more source
Evaluating the Educational Value of Artificial Intelligence in Pharmacotherapy Education
Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.ABSTRACT Final‐year medical students frequently make prescribing errors, partly because they have had insufficient training in therapeutic reasoning. Students need to understand the underlying rationale behind a drug choice in order to subsequently apply that knowledge critically and independently.
Mariëlle G. Hartjes +4 more
wiley +1 more source
Diabetic Medicine, Volume 43, Issue 6, June 2026.Abstract Introduction Type 2 diabetes is a complex condition with a multifactorial pathogenesis. The pathogenesis is considered to be polygenic due to complex interactions between genetic/epigenetic and environmental factors. The aim of this study is to determine the genetic, environmental and lifestyle factors associated with the development of type 2
Sunny Chinenye +18 more
wiley +1 more source
, 2018 There is an unmet need to prevent cardiovascular disease and chronic kidney disease development and progression worldwide. Losartan, the first angiotensin receptor blocker, was shown to exert significant cardioprotective and renoprotective effects in the
Ural, D. +3 more
core +2 more sources
Xiaojun Zhang,1,* Ying Zhao,2,* Zhaogang Teng,3 Tangyao Sun,3 Jun Tao,3 Jiang Wu,4 Yu Wang,3 Fan Qiu,4 Feng Wang4 1Department of Radiology, Children’s Hospital of Nanjing Medical University, Nanjing, 210018, People’s Republic of China ...
Tao J +8 more
core
Effects of Losartan on Capillary Density in Cardiac Muscles of Diabetic Rats
مجله دانشکده پزشکی اصفهان, 2012 Background: Stimulatory and/or inhibitory effects of angiotensin II is attributed to angiotensin receptor I. A few studies investigated the role of angiotensin receptor I on cardiovascular system in diabetic subjects.
Ali Reza Fallahzadeh +2 more
doaj
Losartan therapy in gout patients
, 2008 Aim. To study losartan effectiveness and safety in patients with gout and arterial hypertension (AH).Material and methods. In total, 30 patients not having goat attack were examined (mean age 49,8+10,5 years, disease duration - 6,5 (3,0;16) years). For 8
A. I. Ilyina +2 more
core
Losartan: il valore clinico ed economico
, 2004 Losartan is an angiotensin II receptor antagonist (ARB) that has been proven effective and well tolerated in the treatment of hypertension and in the reduction of global cardiovascular risk, but is more expensive than many alternatives. The present paper
Pradelli, Lorenzo, Eandi, Mario
core +1 more source
Fixed‐Dose Combinations for Hypertension: Barriers to Use and Opportunities for Health Systems
The Journal of Clinical Hypertension, Volume 28, Issue 6, June 2026.ABSTRACT Background: Uncontrolled hypertension is a leading driver of heart disease, chronic kidney disease, heart failure, dementia, stroke, and pregnancy‐related complications. Fixed‐dose combinations (FDCs) are guideline‐endorsed first‐line therapies that improve blood pressure control by reducing pill burden, improving adherence, and targeting ...
Pranay Narang +4 more
wiley +1 more source